Replies to post #102686 on Biotech Values

[jq1234]

These crappy multi-targeted approaches essentially hit so many targets that you can't dose a patient at high enough levels for it not to be toxic.

There are a few successful multi-targeted kinase inhibitors, Nexavar, Sutent, etc. They can find certain indications where multi-target approach works better than single target. They have difficulty to expand into other indications however.

ARQL's ARQ197 is a selective cMet inhibitor, which should be able to combine with other agents successfully for different indications.

Look at the junk Exelixis has been building for years now. All multi-targeted me-too crap. And they have produced nothing but meager results, at best.

They also have very selective target agent as well, so they don't focus on multi-target exclusively. For multi-target inhibitor, the key is to find the right indications. Random Discontinue Trial Nexavar utilized successfully, EXEL is utilizing right now with XL184, is the best way to narrow the most likely to succeed indications.